1,083 results match your criteria Lupus Erythematosus Drug-Induced

Clinical features of tumor necrosis factor-α-inhibitor induced chilblain lupus: A case series.

JAAD Case Rep 2021 Jun 24;12:81-84. Epub 2021 Apr 24.

Department of Dermatology, University of Wisconsin Hospital and Clinics, Madison, Wisconsin.

View Article and Full-Text PDF

The clinical significance of spondin 2 eccentric expression in peripheral blood mononuclear cells in bronchial asthma.

J Clin Lab Anal 2021 Jun 16;35(6):e23764. Epub 2021 May 16.

Department of Respiratory, Hangzhou Children's Hospital, Hangzhou, China.

Background: Bronchial asthma (BA) was a heterogeneous disease characterized by chronic airway inflammation. Spondin 2 (SPON2) was reported to be implicated in the integrin pathway, protein metabolism, and drug-induced lupus erythematosus. The purpose of this study was to evaluate the significance of SPON2 in BA diagnosis and treatment. Read More

View Article and Full-Text PDF

Drug-induced subacute cutaneous lupus erythematosus in previously diagnosed systemic lupus erythematosus patients: A case series.

JAAD Case Rep 2021 Jun 9;12:18-21. Epub 2021 Apr 9.

Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

View Article and Full-Text PDF

Levetiracetam-induced systemic lupus erythematosus.

J R Coll Physicians Edinb 2021 03;51(1):58-60

Neurocare Clinic, Nasik, India.

Systemic lupus erythematosus (SLE) is a rare autoimmune disorder in a physician's practice, commonly presenting in young females. It is rare for SLE to present at a late age. Though SLE is idiopathic, sometimes it can present as an adverse reaction to drugs. Read More

View Article and Full-Text PDF

Association of Oxidative Stress with Disease Activity and Damage in Systemic Lupus Erythematosus: A Cross Sectional Study from a Tertiary Care Centre in Southern India.

Indian J Clin Biochem 2021 Apr 24;36(2):185-193. Epub 2020 Mar 24.

Department of Clinical Immunology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India.

To study oxidative stress in systemic lupus erythematosus (SLE) by estimating serum oxidised LDL (OxLDL), 8-hydroxy-2'-deoxyguanosine (8-OHdG), malondialdehyde (MDA), and total anti-oxidant status and to correlate with SLE disease activity and disease damage. Eighty SLE patients satisfying the Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) 2012 criteria and 80 healthy controls were studied. Exclusion criteria were infections, renal insufficiency, other connective tissue diseases, drug-induced lupus, smoking, alcohol consumption. Read More

View Article and Full-Text PDF

Lupus-Like Glomerulonephritis Associated With Regorafenib, a Multikinase Inhibitor.

Kidney Med 2021 Mar-Apr;3(2):294-298. Epub 2021 Feb 5.

Section of Nephrology, Division of Internal Medicine, University of Texas MD Anderson Cancer Center, Houston, TX.

Drug-induced lupus glomerular diseases have historically been associated with hydralazine, but new drugs that modify the growth, metabolism, and immunity of cells are increasingly found to cause glomerular disease. This includes anti-tumor necrotic factor and other antibody agents used in cancer treatment. Multitarget tyrosine kinases such as regorafenib are increasingly used in metastatic malignancies with good outcomes. Read More

View Article and Full-Text PDF
February 2021

Lupus Cerebritis Refractory to Guideline-Directed Therapy: A Case Report.

J Investig Med High Impact Case Rep 2021 Jan-Dec;9:23247096211008708

SUNY Upstate Medical University, Syracuse, NY, USA.

Systemic lupus erythematosus is an autoimmune disease that affects multiple organs and organ systems, subsequently requiring an elaborate regimen for management. We present the case of a 63-year-old female who developed unrelenting symptoms of drug-induced lupus, which persisted even after the offending agent was withdrawn, unmasking her underlying systemic lupus erythematosus. She continued to develop neuropsychiatric symptoms, including mania and hallucinations, which complicated the management of her disease. Read More

View Article and Full-Text PDF

Evaluating safety and compatibility of anti-tumor necrosis factor therapy in patients with connective tissue disorders.

Ann Transl Med 2021 Mar;9(5):430

Department of Dermatology, Brigham and Women's Hospital & Harvard Medical School, Boston, MA, USA.

Inhibition of the proinflammatory cytokine tumor necrosis factor alpha (TNFα) has been utilized as a treatment strategy for a variety of immune-mediated inflammatory disorders (IMID), including rheumatoid arthritis, Crohn's disease and psoriasis. A wide array of biologic therapies targeting the TNFα molecule, including etanercept, infliximab, certolizumab, golimumab and adalimumab, are routinely used in the care of patients with these conditions. In addition to their therapeutic potential, anti-TNFα agents commonly induce the formation of autoantibodies such as anti-nuclear antibodies and anti-double stranded DNA antibodies; however, the vast majority of these are of IgM isotype and of unclear clinical significance, uncommonly leading to drug-induced autoimmune disease. Read More

View Article and Full-Text PDF

Cardiac Tamponade during Tocilizumab Therapy in a Patient with Rheumatoid Arthritis and Anti-DNA Antibody Positivity.

Intern Med 2021 Mar 29. Epub 2021 Mar 29.

Tokyo Metropolitan Health and Medical Treatment Corporation Ohkubo Hospital, Japan.

Drug-induced lupus (DIL) is a drug-mediated immune reaction with the same symptoms as that of lupus erythematosus. We herein report the first case of tocilizumab-induced lupus syndrome presenting with cardiac tamponade. A 65-year-old man presented with cough, exertional dyspnea, and chest pain after 2 months of tocilizumab therapy for rheumatoid arthritis. Read More

View Article and Full-Text PDF

Toxic epidermal necrolysis-like lupus.

Clin Exp Dermatol 2021 Mar 24. Epub 2021 Mar 24.

Dermatology Department, University Hospitals of Leicester NHS Trust, Leicester Royal Infirmary, Leicester, UK.

Toxic epidermal necrosis (TEN)-like lupus is a rare condition characterized by epidermal loss and mucosal ulceration occurring in patients with acute severe flares of systemic lupus erythematosus. The clinical picture may mimic drug-induced Stevens-Johnson syndrome/TEN; however, the absence of a suitable culprit drug, and the context of acute lupus point to the correct diagnosis. In a case series of three patients, further discriminating features included a slower onset of epidermal loss, more limited mucosal ulceration and a lack of ocular involvement when compared with drug-induced TEN. Read More

View Article and Full-Text PDF

Unusual Presentation of Systemic Lupus Erythematosus in a Young Male: A Case Report.

J Clin Exp Hepatol 2021 Mar-Apr;11(2):264-269. Epub 2020 Jun 12.

Department of Pathology, Kalinga Institute of Medical Science, Bhubaneswar, Odisha, India.

Hepatic involvement in systemic lupus erythematosus (SLE) is common but described infrequently. Liver is usually never the primary organ to be affected in lupus. Again hepatic involvement probably does not carry much prognostic importance though it may correlate with lupus activity. Read More

View Article and Full-Text PDF

Subepithelial autoimmune blistering dermatoses: Clinical features and diagnosis.

J Am Acad Dermatol 2021 Jul 5;85(1):1-14. Epub 2021 Mar 5.

Department of Dermatology, Mayo Clinic, Rochester, Minnesota; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.

Subepithelial autoimmune blistering dermatoses are a group of rare skin disorders that are characterized by the disruption of the dermal-epidermal junction through the action of autoantibodies. The third article in this continuing medical education series explores the background, epidemiology, clinical features, and diagnostic criteria of each of the major subepithelial autoimmune blistering dermatoses, including bullous pemphigoid, pemphigoid gestationis, lichen planus pemphigoides, mucous membrane pemphigoid, linear IgA bullous dermatosis, and dermatitis herpetiformis. Read More

View Article and Full-Text PDF

Tofacitinib-induced subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis.

Mod Rheumatol Case Rep 2021 Feb 18:1-4. Epub 2021 Feb 18.

Department of Rheumatology, Ankara Yıldırım Beyazıt University Medical Faculty, Ankara, Turkey.

Tofacitinib is a Janus kinase inhibitor that is employed in the treatment of several diseases, especially rheumatoid arthritis (RA), to prevent joint damage and reduce disease activity. Drug-induced lupus erythematosus (DILE) is a disorder that is linked to some drugs and is characterised by regression of clinical signs and symptoms after discontinuation of the drug. A 56-year-old woman who was diagnosed with RA for 20 years was admitted to the rheumatology department. Read More

View Article and Full-Text PDF
February 2021

Ileocolic intussusception caused by mass-forming fibro-granulation from healed ulcer masquerading as small bowel lipoma.

Clin J Gastroenterol 2021 Apr 6;14(2):522-530. Epub 2021 Jan 6.

Department of Gastroenterology, St. Luke's International Hospital, 9-1 Akashicho, Chuo-ku, Tokyo, 104-8560, Japan.

Small bowel intussusception in adults is rare. Unlike children, adults with intussusception generally have a causative lead point, of which a majority is benign. We report the case of a 55-year-old woman with systemic lupus erythematosus on steroids and nonsteroidal anti-inflammatory drugs who presented with intermittent melena. Read More

View Article and Full-Text PDF

Antinuclear antibody (ANA) monitoring in drug-induced lupus erythematosus (DILE).

Rheumatology (Oxford) 2021 Apr;60(4):2022-2023

SA Pathology and Flinders Medical Centre.

View Article and Full-Text PDF

Antithyroid Drug-Induced Lupus Erythematosus and Immunoglobulin A Deficiency.

Am J Case Rep 2020 Dec 22;21:e927929. Epub 2020 Dec 22.

Department of Internal Medicine, Brugmann University Hospital, Free University of Brussels (ULB), Brussels, Belgium.

BACKGROUND Antithyroid drugs, namely methimazole, are well-known causes of drug-induced lupus erythematosus. This is, however, an infrequent adverse effect. Selective Immunoglobulin A (IgA) deficiency, in contrast, is the most common primary immunodeficiency. Read More

View Article and Full-Text PDF
December 2020

Drug-induced subacute cutaneous lupus erythematosus associated with abatacept.

Lupus 2021 Apr 22;30(4):661-663. Epub 2020 Dec 22.

Division of Dermatology, Department of Medicine, University of Louisville, Louisville, USA.

Numerous drugs have been linked to the induction or exacerbation of systemic cutaneous lupus erythematosus (SCLE). This report presents the third case of the biologic abatacept as an exacerbating medication for SCLE. A 73-year old woman with a remote history of subacute cutaneous lupus and rheumatoid arthritis, well controlled on hydroxychloroquine, presented with worsening annular erythematous, slightly scaly plaques on her forearms and hands. Read More

View Article and Full-Text PDF

The Effect of Biological Agents on Antinuclear Antibody Status in Patients with Psoriasis: A Single-Center Study.

Indian Dermatol Online J 2020 Nov-Dec;11(6):904-909. Epub 2020 Nov 8.

Department of Dermatology and Venereology, Health Sciences University, Ankara Training and Research Hospital, Turkey.

Background And Aims: Biological agents are being used as treatment of psoriasis for years. However, autoimmunity can develop after the using of these agents. Antinuclear antibody (ANA) status changes during biological therapy can be affected by certain factors including the presence of immunosuppression. Read More

View Article and Full-Text PDF
November 2020

Cutaneous drug eruptions including serum sickness-like reaction, symmetrical drug-related intertriginous and flexural exanthema, and drug-induced lupus.

Clin Dermatol 2020 Nov - Dec;38(6):641-647. Epub 2020 Jun 30.

Wake Forest University School of Medicine, Department of Dermatology, Winston-Salem, North Carolina, USA. Electronic address:

Cutaneous manifestations of drug reactions are common yet vary widely in their appearance and degree of internal organ involvement. Serum sickness--like reactions, symmetrical drug-related intertriginous and flexural exanthem, granulomatous drug eruption, pseudolymphoma, and drug-induced lupus are medication-induced conditions with dermatologic presentations. Many of the conditions discussed are relatively rare but nonetheless demand our attention and understanding. Read More

View Article and Full-Text PDF
January 2021

Advances in Microbiome Detection Technologies and Application in Antirheumatic Drug Design.

Curr Pharm Des 2021 ;27(7):891-899

Department of Bioinformatics, Hangzhou Nuowei Information Technology, Co., Ltd. Hangzhou, China.

Rheumatic diseases are a kind of chronic inflammatory and autoimmune disease affecting the connection or supporting structures of the human body, such as the most common diseases Ankylosing spondylitis (AS), gout and Systemic lupus erythematosus (SLE). Although the precise etiology and pathogenesis of the different types of rheumatic diseases remain mostly unknown, it is now commonly believed that these diseases are attributed to some complex interactions between genetics and environmental factors, especially the gut microbiome. Altered microbiome showed clinical improvement in disease symptoms and partially restored to normality after prescribing disease-modifying antirheumatic drugs (DMARDs) or other treatment strategies. Read More

View Article and Full-Text PDF

Interleukin 4 deficiency limits the development of a lupus-like disease in mice triggered by phospholipids in a non-bilayer arrangement.

Scand J Immunol 2021 Mar 25;93(3):e13002. Epub 2020 Dec 25.

Laboratorio de Biomembranas, Departamento de Bioquímica, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Ciudad de México, México.

Non-bilayer phospholipids arrangements (NPAs) are transient molecular associations different from lipid bilayers. When they become stable, they can trigger a disease in mice resembling human lupus, which is mainly characterized by the production of anti-NPA IgG antibodies. NPAs are stabilized on liposomes or cell bilayers by the drugs procainamide or chlorpromazine, which produce drug-induced lupus in humans. Read More

View Article and Full-Text PDF

Systemic lupus erythematosus and infections.

B K Singh S Singh

Reumatismo 2020 Nov 19;72(3):154-169. Epub 2020 Nov 19.

Pathology, RUHS, Jaipur.

Systemic lupus erythematosus (SLE) is an inflammatory and multi-systemic autoimmune disorder, characterized by an uncontrolled auto-reactivity of B and T lymphocytes, leading to the production of autoantibodies against self-directed antigens and tissue damage. The life expectancy in patients with SLE has improved tremendously in the last two decades, but the mortality rates still remain three times greater compared to those of the general population. Despite increased awareness and improved management, infections remain a major source of morbidity, mortality, hospitalization, and death in patients with SLE. Read More

View Article and Full-Text PDF
November 2020

Characterization of drug-induced cutaneous lupus: Analysis of 1994 cases using the WHO pharmacovigilance database.

Autoimmun Rev 2021 Jan 11;20(1):102705. Epub 2020 Nov 11.

Service de Rhumatologie, Hôpitaux Universitaires de Strasbourg, Laboratoire d'ImmunoRhumatologie Moléculaire, INSERM UMR_S1109, Centre National de Références des Maladies Systémiques et Autoimmunes Rares Est Sud-Ouest (RESO), Université de Strasbourg, F-67000 Strasbourg, France. Electronic address:

View Article and Full-Text PDF
January 2021

[Diagnosis, treatment and prophylaxis of herpes zoster].

Boris Ehrenstein

Z Rheumatol 2020 Dec;79(10):1009-1017

Klinik und Poliklinik für Rheumatologie/Klinische Immunologie, Asklepios Klinikum Bad Abbach, 93077, Bad Abbach, Deutschland.

In the case of reduced cellular immunity the previously dormant varicella zoster virus (VZV) causes the characteristic belt-shaped vesicular exanthema of herpes zoster. The initial clinical symptoms of herpes zoster are often non-specific and may lead to initial misdiagnosis. A common complication of herpes zoster is postherpetic neuralgia (PHN) but secondary hematogenic dissemination is only rarely observed. Read More

View Article and Full-Text PDF
December 2020

[Cytomegalovirus infection in systemic lupus erythematosus patients. A series of 12 case reports and literature review].

P Chabert A Hot

Rev Med Interne 2021 Apr 1;42(4):237-242. Epub 2020 Nov 1.

Service de médecine interne - pavillon O, hôpital Édouard-Herriot, 5, place d'Arsonval, 69003 Lyon, France; Hospices civils de Lyon, Lyon, France. Electronic address:

Introduction: Patients with systemic lupus erythematosus (SLE) are at risk of cytomegalovirus (CMV) infection, due to the disease itself or to drug-induced immunosuppression. Also, active CMV infection may trigger or worsen SLE flare-up.

Methods: In this retrospective single-centre cohort study, we reported all adult inpatients with a diagnosis of SLE, presenting with active and confirmed CMV infection. Read More

View Article and Full-Text PDF

Why thromboembolism occurs in some patients with thrombocytopenia and treatment strategies.

Thromb Res 2020 12 8;196:500-509. Epub 2020 Oct 8.

Department of Cardiovascular Center, Jilin University First Hospital, China. Electronic address:

Platelets play such an important role in the process of thrombosis that patients with thrombocytopenia generally have an increased risk of bleeding. However, abnormal thrombotic events can sometimes occur in patients with thrombocytopenia, which is unusual and inexplicable. The treatments for thrombocytopenia and thromboembolism are usually contradictory. Read More

View Article and Full-Text PDF
December 2020

Dermatologic adverse reactions to proton-pump inhibitors: A synthetized review.

J Cosmet Dermatol 2021 Apr 27;20(4):1073-1079. Epub 2020 Oct 27.

Department of Dermatology, Saint Georges Hospital University Medical Center, Beirut, Lebanon.

Background: Proton-pump inhibitors (PPIs) are one of the most prescribed drugs. Their dermatological adverse reactions are multiple and vary in severity.

Aims: This review discusses all reported cutaneous side effects of PPIs in order to help physicians understand them and provide appropriate management. Read More

View Article and Full-Text PDF

Complication of Mycobacterium tuberculosis treatment: Isoniazid-induced pneumonitis.

Int J Infect Dis 2020 Nov 26;100:411-413. Epub 2020 Sep 26.

Division of Pulmonary & Critical Care Medicine, University of Miami Miller School of Medicine/Jackson Memorial Hospital, Miami, FL, United States.

Prolonged therapy with isoniazid is used for the treatment of pulmonary tuberculosis. Drug-induced lupus erythematosus is a rare, adverse event associated with isoniazid use and can complicate treatment, especially if it is associated with pneumonitis. The diagnosis is made by clinical suspicion, elevated serum titers of anti-nuclear antibody and anti-histone antibody, and new ground-glass opacities on chest tomography. Read More

View Article and Full-Text PDF
November 2020

Hydroxychloroquine early in pregnancy and risk of birth defects.

Am J Obstet Gynecol 2021 03 19;224(3):290.e1-290.e22. Epub 2020 Sep 19.

Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA.

Background: Hydroxychloroquine is generally considered safe in pregnancy for the treatment of rheumatic conditions, but studies have been too small to evaluate teratogenicity. Quantifying the risk of congenital malformations associated with early pregnancy exposure to hydroxychloroquine is important in both the context of its ongoing use for rheumatological disorders and its potential future use for coronavirus disease 2019 prophylaxis, for which a number of clinical trials are ongoing despite initial trials for coronavirus disease 2019 treatment having been negative.

Objective: The study objective was to evaluate the risk of major congenital malformations associated with exposure to hydroxychloroquine during the first trimester of pregnancy, the period of organogenesis. Read More

View Article and Full-Text PDF